Dabrafenib/vemurafenib

  • PDF / 169,833 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 20 Downloads / 144 Views

DOWNLOAD

REPORT

1

Dabrafenib/vemurafenib Pustular psoriasis: case report An 60-year-old man developed pustular psoriasis during treatment with vemurafenib and dabrafenib for melanoma [routes and dosages not stated; not all durations of treatments to reactions onsets stated]. The man with stage IV melanoma, started receiving treatment with BRAF inhibitor vemurafenib and cobimetinib in December 2017. However, 5 months after therapy initiation, he presented with numerous erosive, pustular and crusted lesions over his soles, palms and dorsal aspects of his feet. Additionally, erythematodesquamative lesions were noted on his buttocks and ears. Skin biopsy showed histological changes consistent with pustular psoriasis. Based on the examinations and presenting symptoms, a diagnosis of vemurafenib therapy induced pustular psoriasis was made. The treatment with vemurafenib and cobimetinib was discontinued, and his treatment was started with neotigason. The skin lesions resolved after 4 weeks. Subsequently, he started receiving BRAF inhibitor dabrafenib along with trametinib. Control of the metastatic doisease was noted; however, he again developed some pustular psoriatic lesions on soles and palms. The lesions improved with acitretin. Author comment: "Targeted BRAF inhibition with vemurafenib and dramafenib has dramatically improved the survival rate in metastatic melanoma. Despite their survival benefits, small-molecule inhibitors of BRAF are associated with a wide spectrum of cutaneous adverse effects." Aceituno-Madera P, et al. Vemurafenib-induced pustular psoriasis in a patient with metastatic melanoma: An unreported case. Journal of the American Academy of Dermatology 81 (Suppl. 1): AB435, No. 4, Oct 2019. Available from: URL: http:// 803444093 doi.org/10.1016/j.jaad.2019.10.094 [abstract] - Spain

0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 4 Jan 2020 No. 1785

Data Loading...